Profiling in vitro drug release from subcutaneous implants: A review of current status and potential implications on drug product development

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 4, 2006, Pages 157-170

  Iyer, Sunil S ^a   Barr, William H ^a   Karnes, H Thomas ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Accelerated drug release testing; Implants; In vitro drug release; In vitro in vivo correlation

Indexed keywords

CARMUSTINE; GOSERELIN; HUMAN GROWTH HORMONE; INSULIN; LEUPRORELIN; LEVONORGESTREL; POLYMER; RECOMBINANT NERVE GROWTH FACTOR; XENON 133;

CONTROLLED DRUG RELEASE; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DOSAGE FORM; DRUG IMPLANT; DRUG MONITORING; DRUG RELEASE; DRUG RESEARCH; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL INSTRUMENTATION; MEDICAL LITERATURE; METHODOLOGY; NEEDLE; NONHUMAN; PUBLICATION; REVIEW; SURGICAL TECHNIQUE; WORKSHOP;

DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG IMPLANTS; PHARMACEUTICAL PREPARATIONS; SUBCUTANEOUS TISSUE; TECHNOLOGY, PHARMACEUTICAL;

EID: 33744469328     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.493     Document Type: Review

References (88)

1. Gray V. Dissolution Testing: An Overview and a Summary of Recent Trends and Regulatory Activities. V. A. Gray Consulting Inc.: DE, Website: http://www.tabletscapsules.com/free/tc_2003100_20.pdf [15 April 2004].
2. Sirisuth N, Eddington ND. In vitro-in vivo correlation definitions and regulatory guidance. Int J Generic Drugs. Website: http://www.locumusa.com/pdf/members/ivivc-01.pdf [21 January 2004].
3. Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy. J Surg Res 1964; 4: 139-142.
4. Ballard BE. The physicochemical properties of drugs that control their absorption rate after implantation. Ph.D. Thesis, University of California, San Francisco, 1961.
5. Davis BK. Diffusion in polymer gel implants. Proc Natl Acad Sci 1974; 71: 3120-3123.
6. Mohl S, Reithmeier H, Winter G. Poster presentation: sustained release of BSA from implant systems by using physiological lipids. Colorado Protein Stability Conference, Breckenbridge, CO, July 2002, Website: http://www.chemie.uni-muenchen.de/pb/aks/winter/ Mohl_poster_denver_072002.pdf [17 October 2003].
7. Okumu FW, Cleland JL. Implants and injectables. In Modified-Release Drug Delivery Technology, Rathbone MJ, Hadgraft J, Roberts MS (eds). Marcel Dekker Inc.: New York, 2003; 633-638.
8. Langer R, Peppas NA. Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J 2003; 49: 2990-3006.
9. Stevenson CL, Theeuwes F, Wright JC. Osmotic implantable delivery systems. In Handbook of Pharmaceutical Controlled Release Delivery, Wise DL (ed.). Marcel Dekker Inc.: New York, 2000; 225-254.
10. Eckenhoff B, Theeuwes F, Urquhart F. Osmotically actuated dosage forms for rate-controlled drug delivery. Pharm Technol 1987; 11: 96-105.
11. Pharmacopeial Previews. <1092> The dissolution procedure: development and validation. Pharm Forum 2004; 30: 351-363.
12. Burgess DJ, Crommelin DJA, Hussain AS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS Pharm Sci 2004; 6: article 11.
13. Sunkara G, Chilukuri DM. IVIVC: an important tool in the development of drug delivery systems. Drug Delivery Technol. Website: http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=144 [7 February 2004].
14. Uppoor VRS. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Rel 2001; 72: 127-132.
15. FDA. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlations, 1997.
16. Shah J. Presentation: in vitro-in vivo correlation (IVIVC) for parenteral sustained release formulations. AAPS Annual Meeting and Exposition: Sunrise School Session 'IVIVC: A Useful Tool in the Development of Drug Delivery Systems', Baltimore, MD, November 2004.
17. Rohrs BR. Dissolution method development for poorly soluble compounds. Diss Tech 2001; 8: 1-5.
18. Banakar UV. Dissolution testing devices. In Pharmaceutical Dissolution Testing, Swarbrick J (ed.). Marcel Dekker Inc.: New York, 1992; 53-105.
19. Levy G. Effect of certain tablet formulation factors on dissolution rate of the active ingredient I: importance of using appropriate agitation intensities for in vitro dissolution rate measurements to reflect in vivo conditions. J Pharm Sci 1963; 52: 1039-1046.
20. <711> Dissolution. USP24/NF19. The United States Pharmacopeial Convention. Rockville, MD, 2000; 1941-1943.
21. Barzilay RB, Hersey JA. Dissolution rate measurement by an automated dialysis method. J Pharm Pharmacol 1968; 20(Suppl): 232S-238S.
22. Langenbucher F. In vitro assessment of dissolution kinetics: description and evaluation of a column-type method. J Pharm Sci 1969; 58: 1265-1272.
23. Wagner JG. Biopharmaceutics and Relevant Pharmacokinetics. Drug Intelligence Publications: IL, 1971; 110-114.
24. Schliecker G, Schmidt C, Fuchs S, Ehinger A, Sandow J, Kissel T. In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis. J Control Rel 2004; 94: 25-37.
25. Malmsten M. Degradation of surfactants and polymers in drug delivery. In Surfactants and Polymers in Drug Delivery, Swarbrick J (ed.). Marcel Dekker Inc.: New York, 2002; 293-317.
26. Shah VP, Siewert M, Dressman J, Moeller H, Brown CJ. Dissolution/in vitro release testing of special dosage forms. Diss Tech 2002; 9: 1-5.
27. <724> Drug Release/Physical Tests. USP24/NF19. The United States Pharmacopeial Convention. Rockville, MD, 2000; 1945-1946.
28. Siewart M, Dressman J, Brown C, Shah VP. FIP/AAPS Guidelines for dissolution/in vitro release testing of novel/special dosage forms. Diss Tech 2003; 10: 6-15.
29. Nicolaides E, Hempenstall JM, Reppas C. Biorelevant dissolution tests with the flow-through apparatus? Diss Tech 2000; 7: 8-15.
30. Fyfe CA, Grondey H, Blazek-Welsh AI, Chopra SK, Fahie BJ. NMR imaging investigations of drug delivery devices using a flow-through USP dissolution apparatus. J Control Rel 2000; 68: 73-83.
31. Porter CJH, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000; 89: 297-310.
32. Langevin HM, Cornbrooks CJ, Taatjes DJ. Fibroblasts form a body-wide cellular network. Histochem Cell Biol 2004; 122: 7-15.
33. Aukland K, Reed RK. Interstitial lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 1993; 73: 1-78.
34. Watson PD, Grodrins FS. An analysis of the effects of interstitial matrix on plasma-lymph transport. Microvasc Res 1978; 16: 19-41.
35. Bert JL, Mathieson JM, Pearce RH. The exclusion of human serum albumin by human dermal collagenous fibres and within human dermis. Biochemical J 1982; 201: 395-403.
36. Whang JM, Quinn JA, Graves DJ, Neufeld GR. Permeation of inert gases through human skin: modeling the effect of skin blood flow. J Appl Physiol 1989; 67: 1670-1686.
37. Pappanheimer JR, Renkin EM, Borrero LM. Filtration, diffusion and molecular sieving through peripheral capillary membranes: a contribution to the Pore theory of capillary permeability. Am J Physiol 1951; 167: 13-46.
38. Renkin EM. Filtration, diffusion and molecular sieving through porous cellulose membranes. J Gen Physiol 1954; 38: 225-243.
39. Renkin EM. Multiple pathways of capillary permeability. Circ Res 1977; 41: 735-743.
40. Renkin EM. Transport of large molecules across capillary walls. Physiol 1964; 7: 13-28.
41. Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care 1982; 5: 77-91.
42. Simonsen L, Enevoldsen LH, Bülow J. Determination of adipose tissue blood flow with local 133Xe clearance. Evaluation of a new labeling technique. Clin Physiol Funct Imaging 2003; 23: 320-323.
43. Enevoldsen LH, Simonsen L, Stallknecht B, Galbo H, Bülow J. In vivo human lipolytic activity in preperitoneal and subdivisions of subcutaneous abdominal adipose tissue. Am J Physiol Endocrinol Metab 2001; 281: E1110-E1114.
44. Sindrup JH, Kastrup J, Jorgensen B, Bülow J, Lassen NA. Nocturnal variations in subcutaneous blood flow rate in lower leg of normal human subjects. Am J Physiol Heart Circ Physiol 1991; 260: H480-H485.
45. Zuidema J, Pieters FAJM, Duchateau GSMJE. Release and absorption rate aspects of intramuscularly injected pharmaceuticals. Int J Pharm 1988; 47: 1-12.
46. Qureshi SA, Caillé G, Brien R, McGilveray IJ. Drug release characterization of extended-release nifedipine products using a flow-through dissolution apparatus. Proc Int Symp Control Rel Bioact Mater 1994; 21: 668.
47. Qureshi SA, Caillé G, Brien R, Piccirilli G, Yu V, McGilveray IJ. Application of flow-through dissolution method for the evaluation of oral formulations of nifedipine. Drug Dev Ind Pharm 1994; 20: 1869-1882.
48. Cammarn S, Sakr A. Predicting dissolution via hydrodynamics: salicylic acid tablets in flow through cell dissolution. Int J Pharm 2000; 201: 199-209.
49. Waymouth C. The nutrition of animal cells. Int Rev Cytol 1954; 3: 1-68.
50. Waymouth C. Osmolality of mammalian blood and of media for culture of mammalian cells. In Vitro 1970; 6: 109-127.
51. Lelong IH, Rebel G. pH drift of 'physiological buffers' and culture media used for cell incubation during in vitro studies. J Pharm Toxicol Methods 1998; 39: 203-210.
52. Chidambaram N, Burgess DJ. A novel in vitro release method for submicron sized dispersed systems. AAPS Pharm Sci 1999; 1: article 11.
53. Pitt CG. Biodegradable drug delivery systems based on aliphatic polyesters: application to contraceptives and narcotic antagonists. In Controlled Release of Bioactive Materials, Baker R (ed.). Academic Press Inc.: New York, 1980; 19-43.
54. Pitt CG. Poly-ε-caprolactone and its copolymers. In Biodegradable Polymers as Drug Delivery Systems, Chasin M, Langer R (eds). Marcel Dekker Inc.: New York, 1990; 71-120.
55. Park K, Shalaby WSW. Biodegradation. In Biodegradable Hydrogels for Drug Delivery, Park K, Shalaby WSW, Park H (eds). Technomic Publishing Co., Inc.: Pennsylvania, 1993; 13-34.
56. Stenken JA, Reichert WM, Klitzman B. Magnetic resonance imaging of a tissue/implanted device biointerface using in vivo microdialysis sampling. Anal Chem 2002; 74: 4849-4854.
57. Wisniewski N, Klitzman B, Miller B, Reichert WM. Decreased analyte transport through implanted membranes: differentiation of biofouling from tissue effects. J Biomed Mater Res 2001; 57: 513-521.
58. Folley SJ. 'Ghost' formation in subcutaneously implanted tablets of synthetic estrogens. Nature 1942; 150: 403-404.
59. Bishop PMF, Folley SJ. Implantation of testosterone in cast pellets. Lancet 1944; 1: 434-435.
60. Lewin J, Huidobro F. On the absorption mechanism of pellets. Acta Physiol Latinoamericana 1953; 3: 17-24.
61. <1088> In vitro and In vivo Evaluation of Dosage Forms. USP24/ NF19. The United States Pharmacopeial Convention. Rockville, MD, 2000; 2051-2056.
62. <1225> Validation of Compendial Methods. USP24/NF19. The United States Pharmacopeial Convention. Rockville, MD, 2000; 2149-2152.
63. FDA. Draft Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms containing certain Active Moieties/Active Ingredients based on Biopharmaceutical Classification System, 1999.
64. Kasim NA, Whitehouse M, Ramachandran C, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85-96.
65. Rohrs BR, Skoug JW, Halstead GW. Dissolution assay development for in vitro-in vivo correlations. In In Vitro-In Vivo Correlations, Young D, Devane JG, Butler J (eds). Plenum Press: New York, 1997; 17-30.
66. Lin S, Chao PY, Chien YW, et al. In vitro and in vivo evaluations of biodegradable implants for hormone replacement therapy: effect of system design and PK-PD relationship. AAPS Pharm Sci Tech 2001; 2: article 16.
67. Siewert B, Siewert M. Dissolution tests for ER products. Dissolution Technologies website: http://www.dissolutiontech.com/Dtresour/1198art/Nov98Art1.html [4 February 2004].
68. FIP Guidelines for Dissolution Testing of Solid Oral Products, 1997.
69. FDA. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, 1997.
70. Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Technol 1996; 20: 64-74.
71. Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison - statistics and analysis of the similarity factor, f2. Pharm Res 1998; 15: 889-896.
72. Sathe P, Tsong Y, Shah VP. In vitro dissolution profile comparison: statistics and analysis, model dependent approach. Pharm Res 1996; 13: 1799-1803.
73. Burgess DJ. Presentation: new apparatus design: dispersed systems, stents and other implantable devices. AAPS Workshop on Dissolution: New Technologies and Regulatory Initiatives, Bethesda, MD, March 2004.
74. Rackley RJ. Examples of in vitro-in vivo relationships with a diverse range of quality. Figure 3. In In Vitro-In Vivo Correlations, Young D, Devane JG, Butler J (eds). Plenum Press: New York, 1997; 1-15.
75. Hwang SS, Bayne W, Theeuwes F. In vivo evaluation of controlled-release products. J Pharm Sci 1993; 82: 1145-1150.
76. Gray V. Controlled release society annual meeting report: dissolution highlights. Diss Tech 2004; 11: 30-31.
77. Skelly JP, Yau MK, Elkins JS, Yamamoto LA, Shah VP, Barr WH. Topographical dissolution characterization for controlled release products - a new technique. Drug Dev Ind Pharm 1986; 12: 1159-1175.
78. Skelly JP, Yamamoto LA, Shah VP, Yau MK, Barr WH. In vitro topographical characterization as a predictor of in vivo controlled release quinidine gluconate bioavailability. Drug Dev Ind Pharm 1986; 12: 1177-1201.
79. Young D, Chilukuri D, Becker R, Bigora S, Farrell C, Shepard T. Approaches to developing a Level-A IVIVC for injectable dosage forms. Website: www.globomaxservice.com/resource/LevelAIVIVCPoster.pdf [30 October 2004].
80. Shameem M, Lee H, DeLuca PP. A short-term (accelerated release) approach to evaluate peptide release from PLGA depot-formulations. AAPS Pharm Sci 1999; 1: article 7.
81. Zackrisson G, Östling G, Skagerberg B, Anfält T. Accelerated dissolution rate analysis (ACDRA) for controlled release drugs. Application to Roxiam. J Pharm Biomed Anal 1995; 13: 377.
82. Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS Pharm Sci 2002; 4: article 7.
83. Quist PO, Östling G. Accelerated dissolution testing for improved quality assurance. J Pharm Biomed Anal 2002; 28: 1081-1089.
84. Scott P. Process analytical technology: applications to the pharmaceutical industry. Diss Tech 2002; 9: 6-9.
85. Makino K, Arakawa M, Kondo T. Preparation and in vitro degradation properties of polylactide microcapsules. Chem Pharm Bull 1985; 33: 1195-1201.
86. Storey DE. The role of dissolution testing in the design of immediate release dosage forms. Drug Inf J 1996; 30: 1039-1044.
87. FDA. Summary Progress Report: Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach. Website: http://www.fda.gov/cder/gmp/21stcenturysummary.htm [31 August 2004].
88. Wood JH. Dissolution rediscovered. In Pharmaceutical Dissolution Testing, Swarbrick J (ed.). Marcel Dekker Inc.: New York, 1992; 420.